Japan approves Leqembi Pen subcutaneous dosing for early Alzheimer’s
BioArctic said partner Eisai gained Japanese approval for Leqembi Pen, a once-weekly 500 mg subcutaneous autoinjector for early Alzheimer’s, complementing the IV form.
Site Search
Search market news
Find public news by keyword, exact ticker, category and date.
Matching instruments
Open a ticker page for its news coverage. The news search below stays a text search.